Corcept Reports Positive Phase 3 Data In Ovarian Cancer Treatment, Stock Up

(RTTNews) - Corcept Therapeutics (CORT), Monday announced that its Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer met its primary endpoint, showing a 30 percent reduction in disease progression risk.

Patients receiving the combination had a median progression-free survival of 6.5 months versus 5.5 months for chemotherapy alone. Interim results also showed a significant overall survival benefit.

Relacorilant was well-tolerated, with no new safety concerns. Full trial results will be presented later this year, and Corcept plans to submit regulatory applications in the coming months.

CORT is currently trading at $102.26, up $47.63 or 87.20 percent on the Nasdaq.